Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIMSUM: Allogeneic Stem Cell Transplantation with CAMPATH 1H for Hematologic Malignancy
NCT00048412Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Jun 2000
- Primary completion
- Nov 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of alemtuzumab in myelodysplastic syndromes (MDS), leukemia, multiple myeloma (MM) and 3 more (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Treatment Related Mortality. Started Jun 2000; status: completed.
02
Drugs
alemtuzumab
03
Conditions
myelodysplastic syndromes (MDS)leukemiamultiple myeloma (MM)plasma cell dyscrasia (PCD)lymphoproliferative disorders (LPD)
Beyond the preview
Go deeper on NCT00048412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048412.